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The Journal of Immunology
Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To
Suppress T Cell Activation and To Promote Regulatory T Cell
Expansion
Seth B. Coffelt,* Yung-Yi Chen,* Munitta Muthana,* Abigail F. Welford,* Andrea O. Tal,†
Alexander Scholz,† Karl H. Plate,† Yvonne Reiss,† Craig Murdoch,‡ Michele De Palma,x
and Claire E. Lewis*
Angiopoietin 2 (ANGPT2) is a proangiogenic cytokine whose expression is often upregulated by endothelial cells in tumors.
Expression of its receptor, TIE2, defines a highly proangiogenic subpopulation of myeloid cells in circulation and tumors called
TIE2-expressing monocytes/macrophages (TEMs). Genetic depletion of TEMs markedly reduces tumor angiogenesis in various
tumor models, emphasizing their essential role in driving tumor progression. Previously, we demonstrated that ANGPT2 aug-
ments the expression of various proangiogenic genes, the potent immunosuppressive cytokine, IL-10, and a chemokine for
regulatory T cells (Tregs), CCL17 by TEMs in vitro. We now show that TEMs also express higher levels of IL-10 than TIE22
macrophages in tumors and that ANGPT2-stimulated release of IL-10 by TEMs suppresses T cell proliferation, increases the
ratio of CD4+ T cells to CD8+ T cells, and promotes the expansion of CD4+CD25highFOXP3+ Tregs. Furthermore, syngeneic
murine tumors expressing high levels of ANGPT2 contained not only high numbers of TEMs but also increased numbers of Tregs,
whereas genetic depletion of tumor TEMs resulted in a marked reduction in the frequency of Tregs in tumors. Taken together, our
data suggest that ANGPT2-stimulated TEMs represent a novel, potent immunosuppressive force in tumors. The Journal of
Immunology, 2011, 186: 4183–4190.
T
IE2-expressing monocytes/macrophages (TEMs) are a
subpopulation of myeloid cells characterized by the ex-
pression of monocyte/macrophage markers as well as the
angiopoietin receptor TIE2 (1, 2). TEMs are found in circulation
and tumors of both human and mice, and conditional TEM de-
letion in various mouse tumor models has established their pro-
found effect on tumor angiogenesis and progression (2–4). We
recently reported that human circulating TEMs are preprogrammed
in the bone marrow or peripheral blood for proangiogenic functions
before these cells reach the tumor microenvironment (5). We also
found that exposure to angiopoietin 2 (ANGPT2)—a cytokine over-
expressed by endothelial cells in tumors (6–8)—further augments
the ability of TEMs to stimulate angiogenesis through upregula-
tion of such proangiogenic enzymes as thymidine phosphorylase
and cathepsin B (5).
In addition, we demonstrated that ANGPT2 skews the phenotype
of human TEMs toward an M2-like macrophage polarization
in vitro via downregulation of IL-6 and increased expression of
mannose receptor (MRC1), CCL17, and IL-10 (5, 9, 10). TEMs
display several characteristics of M2-polarized macrophages in
murine tumors (11), and our data indicate that ANGPT2 may drive
this phenotype (5). Because M2 macrophages are thought to
promote tumor progression through angiogenesis as well as sup-
pression of antitumor immune responses (reviewed in Refs. 10 and
12), we hypothesized that ANGPT2 may stimulate the immuno-
suppressive properties of TEMs.
In this paper, we show that ANGPT2-stimulated human TEMs
suppress T cell proliferation and expand CD4+CD25+FOXP3+
regulatory T cells (Tregs) via IL-10–dependent mechanisms. We
also demonstrate that murine tumor TEMs express high levels of
IL-10 and are markedly immunosuppressive. These data illustrate
a novel protumorigenic role for TEMs.
Materials and Methods
Human leukocyte isolation, coculture, and flow cytometry
Monocytes were isolated from human Buffy coats as described previously
(3, 5). Autologous CD3+ T cells were isolated by negative selection using
StemCell Technologies’ Rosettesep kit. CD3+ cells were labeled with 10
mM CFSE (Invitrogen). A 1:1 ratio of 53 105 monocytes to 53 105 CD3+
cells were cocultured in the presence of CD3/28 Dynabeads (Invitrogen)
and cytokines for 5 d. Cocultures were also performed with 0.4-mm
Transwell inserts. Recombinant human cytokines (R&D Systems) were
added at the following concentrations: 300 ng/ml ANGPT2, 100 U/ml
IFN-g, and 5 ng/ml IL-4. CD3+ cells cultured without monocytes, un-
labeled CD3+ cells, and cocultures without beads served as experimental
controls. Neutralizing anti–IL-10 (clone 23738; R&D Systems) or IgG
control was used at 5 mg/ml. Following incubation, cells were removed
from culture dishes, washed, resuspended in HBSS/0.5% BSA, and
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blocked with an FcR blocking reagent (Miltenyi Biotec) for 10 min at 4˚C.
Cells were stained with Pacific Blue-conjugated CD14 (1:20, clone M5E2;
BD Biosciences), Alexa Fluor 647-conjugated CD3 (1/20, clone OKT3;
eBioscience), PE-Cy7–conjugated CD4 (1/20, clone GK1.5; eBioscience),
Alexa Fluor 700-conjugated CD8 (1/10, clone OKT8; eBioscience), PE-
conjugated CD25 (1/20, clone BC96; eBioscience), or isotype controls for
30 min at 4˚C and then washed. Cells were permeabilized using Cytofix/
Cytoperm solutions and then stained with PerCP-Cy5.5–conjugated FOXP3
(1/20, clone PCH101; eBioscience) or isotype control. Cells were analyzed
on an LSR II flow cytometer (BD Biosciences) using FlowJo software (Tree
Star). Compensation was calculated by CompBeads (BD Biosciences), ac-
cording to the manufacturer’s instructions. Experiments were repeated at
least three times.
Mice and cell lines
Tie1-tTA–driven human ANGPT2 double-transgenic (DT) mice were gen-
erated as described previously (5, 13, 14). ANGPT2 DT and wild-type
(WT) control mice were depleted of doxycycline 2 wk before implanta-
tion of tumor cells. Syngeneic Lewis lung carcinoma cells (2 3 106) were
inoculated s.c. and allowed to propagate for 2 wk. Animals were cared for
in accordance with German Legislation on the Care and Use of Laboratory
Animals.
To generate tumors without TEMs, syngeneic N202.1A mammary tumor
cells were injected into FVB mice (Charles River Laboratories) who had
received bone marrow transplantation from FVB/Tie2-tk transgenic mice
(2). Mice were then given gancyclovir (GCV) to specifically deplete TEMs
or PBS as control. Tumors were harvested after 3 wk. All procedures were
conducted in accordance with the Animal Care and Use Committee of the
Fondazione San Raffaele del Monte Tabor (IACUC 324,335) and com-
municated to the Ministry of Health in Italy and local authorities in Milan.
MMTV-PyMT mice on the FVB/n-Tg background were a gift from
Z. Werb (University of California, San Francisco, San Francisco, CA).
Late-stage mammary tumors were excised at 11–12 wk. 4T1 cells were
maintained as described previously (15). BALB/c mice (Harlan Labora-
tories) at 5 wk old were injected s.c. with 106 4T1 mammary carcinoma
cells. Animal experiments were conducted in accordance with U.K. Home
Office regulations and were approved by the University of Sheffield Ethi-
cal Committee.
Immunofluoresence confocal microscopy
Detection of tumor-associated T cells in frozen tumor sections was per-
formed using eFluor660-conjugated anti-CD3 (1/80, clone 17A2), PE-
conjugated anti-CD4 (1/160, clone GK1.5), and FITC-conjugated anti-
FOXP3 (1/50, clone FJK-16s) or isotype controls all purchased from
eBioscience. Nuclei were highlighted using 30 nM DAPI (Invitrogen).
Images were captured by using a Zeiss LSM 510 laser scanning confocal
microscope. Further details about microscopy and experimental procedure
can be found in Ref. 5.
Flow cytometry and FACS of murine cells
PyMT and 4T1 tumors were digested with 1 mg/ml collagenase type IV
(Sigma-Aldrich) in HBSS for 1 h at 37˚C in an orbital shaker. Cells were
washed in HBSS containing 5% FBS twice and then resuspended in HBSS
containing 0.5% BSA. After blocking in 10% goat serum (Vector Labo-
ratories) for 10 min at 4˚C, cells were incubated with FITC-conjugated F4/
80 (1/25, clone CI:A3-1; AbD Serotec), PE-conjugated anti-murine TIE2
(1/50; eBioscience), Alexa Fluor 700-conjugated CD11b (1/50; clone M1/
70; eBioscience), FITC-conjugated anti-FOXP3 (1/50, clone FJK-16s
eBioscience), PE-conjugated anti-CD4 (1/100; clone GK1.5; eBioscience),
Alexa Fluor 700-conjugated CD3 (1/100; clone 17A2; eBioscience), or
isotype controls for 30 min at 4˚C and then washed. Cells were permea-
bilized using Cytofix/Cytoperm solutions. Alexa Fluor 647-conjugated IL-10
(1/50, clone JES5-16E3; eBioscience) or isotype control was added for 30
min at 4˚C. Cells were analyzed on an LSR II flow cytometer using FlowJo
software.
For FACS, 4T1 single-cell suspensions were stained with anti-F4/80 and
anti-TIE2 as described above. F4/80+TIE22 tumor-associated macrophages
(TAMs) and F4/80+TIE2+ TEMs were isolated as shown in Supplemental
Fig. 1 by using BD FACSAria (BD Biosciences). Spleens from tumor-
bearing animals were stained with PE-conjugated anti-CD3 (eBioscience),
anti-CD11b and anti–Gr1-Alexa Fluor 350 (1/10; BD Biosciences). TO-
PRO-3 (Invitrogen) was used to measure viability. Myeloid cell subpopu-
lations and CFSE-labeled splenic T cells were cocultured for 3 d in the
presence of mouse CD3/CD28 Dynabeads (Invitrogen) and 500 ng/ml anti–
IL-10 (clone JES052A5; R&D Systems) or control IgG where indicated.
After coculture, cell death and CFSE fluorescence were measured using
LSR II cytometer and analyzed with FlowJo software.
Western blot analysis
4T1 tumors were homogenized in T-PER protein extraction buffer (Pierce)
with protease inhibitors and EDTA. Protein concentration was determined
using the bicinchoninic acid method. A 12% SDS-polyacrylamide gel was
loaded with 40 mg protein for separation and then transferred to nitro-
cellulose. The membrane was blocked with 5% milk protein in TBS-0.2%
Tween 20. Anti-ANGPT2 (1/500; Calbiochem) or anti–IL-10 (1/500; R&D
Systems) was incubated with the membrane overnight at 4˚C and then
washed four times in TBST. Anti-rabbit or anti-rat Abs conjugated with
HRP were incubated for 1 h at room temperature. Bands were visualized
by ECL. Stripped blots were probed with b-actin (1/5000; Sigma-Aldrich).
At least two tumors were analyzed for every time point.
Statistical analysis
One-way ANOVA, followed by Newman-Keuls post test, was used to
determine p values by using GraphPad Prism software. A p value ,0.05
was considered statistically significant. All data shown are means 6 SEs.
Results
ANGPT2-treated human TEMs suppress T cell proliferation
Because our previous studies showed that ANGPT2 upregulates
IL-10 in TEMs (5), we investigated whether ANGPT2 can convert
FIGURE 1. ANGPT2-stimulated human TEMs suppress T cell pro-
liferation. Human CD14+ monocytes were cocultured with CFSE-labeled
CD3+ T cells in the presence of CD3/CD28 Dynabeads, 300 ng/ml
ANGPT2, 100 U/ml IFN-g, 5 ng/ml IL-4, or medium alone (control).
Cocultures were incubated with a nonspecific IgG or neutralizing IL-10 Ab
where indicated. After 5 d, CFSE fluorescence was assessed by flow
cytometry on CD142CD3+-gated cells. A, Representative histograms of T
cell proliferation with percentages of the gated cells shown. B, Graphic
representation of the change in percentage of gated cells from A (expressed
as percentage of control). Pooled data from six independent experiments
are shown. *p, 0.05, ***p, 0.001 as compared with control, ‡‡p, 0.01
as compared with IL-4, ††p, 0.01 as compared with control + IgG, xxp,
0.01 as compared with ANGPT2 + IgG.
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these cells into immunosuppressive cells. Human monocytes and
autologous CD3+ lymphocytes were cocultured in the presence of
ANGPT2 or medium alone. IFN-g and IL-4 were used as controls
in coculture assays as they induce an M1/immunostimulatory and
M2/immunosuppressive phenotype in monocytes, respectively
(9, 10, 16). Monocytes in medium alone had some suppressive
function corroborating results from other laboratories (17), and
this was significantly enhanced by exposure to the type II/Th2
cytokine IL-4 (Fig. 1). Treatment of cocultures with the type I/
Th1 cytokine IFN-g increased T cell proliferation. Strikingly,
ANGPT2-treated TEMs not only suppressed T cell proliferation
when compared with control but also its effect was significantly
greater than that seen with IL-4 (Fig. 1B). Proliferation of CD3+
T lymphocytes cultured without monocytes was not inhibited by
the cytokines tested (data not shown). TIE2 receptor expression
was never detected on cultured T cells or during coculture with
monocytes (data not shown). Moreover, the suppressive effect of
ANGPT2-treated TEMs was not due to increased differentiation
of the monocytes into macrophages, because CD14 expression on
ANGPT2-treated cells was significantly greater than control cells
(data not shown).
Addition of an IL-10–neutralizing Ab, but not a control Ab,
significantly reversed the suppressive functions of ANGPT2-treated
monocytes (Fig. 1B), indicating that ANGPT2-induced IL-10 me-
diates the suppressive ability of TEMs. However, TEM-T cell
contact was also required, because inhibition of ANGPT2-induced
IL-10 in coculture experiments using Transwell inserts did not
significantly reduce T cell suppression (data not shown).
Treg expansion is induced by human TEMs exposed to
ANGPT2
We next investigated individual T cell populations in our lympho-
cyte/monocyte cocultures to determine whether they were affected
by cytokine-treated monocytes. We gated on CD4+ and CD8+ cells
and calculated their frequency. The percentage of CD4+ cells sig-
nificantly increased, and CD8+ cells decreased with ANGPT2
treatment when compared with control (Fig. 2). Interestingly,
ANGPT2 induced a prominent CD3+CD4high T cell population that
was not observed with IFN-g, IL-4, or control groups. Moreover,
neutralization of ANGPT2-induced IL-10 reversed this ratio back
toward control frequencies. These data suggest that ANGPT2 skews
the ratio of CD8+ cytotoxic T lymphocytes to CD4+ cells in favor of
the latter.
We then gated on CD4+ T cells and analyzed expression of
CD25 and FOXP3—two markers of Tregs (17, 18). In the
ANGPT2-treated group, CD4+CD25highFOXP32 cells were sig-
nificantly more abundant than control, indicating an increased
activation status of the CD4+ population (Fig. 3A). In addition,
ANGPT2-treated TEMs induced significant expansion of CD4+
CD25+FOXP3+ cells when compared with control and IL-4–
treated TEMs. IFN-g and IL-4 treatment had no effect when
compared with control (Fig. 3A, 3B). Monocytes were required for
expansion of CD4+CD25+FOXP3+ cells, because cytokines alone
did not affect the T cells (data not shown). The expansion of CD4+
CD25+FOXP3+ cells by ANGPT2-treated TEMs was inhibited by
neutralization of IL-10 but not by control Abs, underscoring the
functional importance of this cytokine in the generation of Tregs.
FIGURE 2. TEMs exposed to ANGPT2 increase
CD4+ T cell frequency. Human CD14+ monocytes
were cocultured with CFSE-labeled CD3+ T cells in
the presence of CD3/CD28 Dynabeads, 300 ng/ml
ANGPT2, 100 U/ml IFN-g, 5 ng/ml IL-4, or medium
alone (control). ANGPT2-treated monocyte/T cell
cocultures were also incubated in the presence of
nonspecific IgG or neutralizing IL-10 Ab. After 5 d,
the proportion of T cell subpopulations was assessed
by flow cytometry on CD142CD3+-gated cells. A,
Representative dot plots with percentages of the gated
cells shown. B, Graphic representation of the per-
centage of gated cells from A (expressed as percentage
of control). Pooled data from six independent experi-
ments are shown. *p, 0.05 as compared with control;
†p , 0.05, †††p , 0.001 as compared with control +
IgG, xp , 0.05, xxxp , 0.001 as compared with
ANGPT2 + IgG.
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After coculture with ANGPT2-treated and control monocytes,
the nonadherent T cells were added to CFSE-labeled, autologous
CD3+ T cells and incubated for another 5 d. The cells induced by
ANGPT2-treated TEMs significantly suppressed T cell prolifera-
tion when compared with control (Fig. 3C). These data indicate
that the Tregs expanded by ANGPT2-treated TEMs exhibit sup-
pressive properties.
Tregs are more abundant in ANGPT2-overexpressing tumors
Given the observations above, we next investigated whether ex-
posure of tumor TEMs to high levels of ANGPT2 in the tumor
microenvironment correlates with increased numbers of tumor
Tregs. Tumors were propagated in ANGPT2 DT or WT mice as
before (5, 14), and then, Tregs were identified as CD3+CD4+
FOXP3+ cells. As shown in Fig. 4A and 4B, both the total number
of Tregs and the proportion of FOXP3+ cells in the CD3+CD4+
population were significantly increased in ANGPT2 DT tumors
when compared with WT tumors (Fig. 4A, 4B). This observation
was not due to the general infiltration of T cells, because neither
the number of CD3+ T cells nor the number of CD3+CD4+ cells
was significantly different between tumor types (Fig. 4B). The
proportion of CD3+CD4+ cells was also similar between tumors
overexpressing ANGPT2 and WT tumors (Fig. 4B).
Tregs are reduced in murine mammary tumors following
genetic depletion of TEMs
We then examined the effect of TEM depletion on the number of
Tregs in N202 mammary tumors by using the conditional model
described previously (2). In tumors without TEMs (GCV), there
was a trend toward greater CD3+ T cell infiltration (Fig. 4D). Both
the total number of CD4+ T cells and the percentage of CD4+ cells
among the entire CD3+ population were significantly increased,
indicative of an antitumor immune response (Fig. 4D). The total
number of CD3+CD4+FOXP3+ cells did not significantly differ
between tumors with TEMs (PBS) and without TEMs (GCV) (Fig.
4C, 4D). However, the proportion of FOXP3-expressing CD3+
CD4+ cells was significantly decreased in TEM-depleted tumors,
suggesting that TEMs suppress antitumor immunity by expanding
or recruiting the Treg population into tumors.
Tumor TEMs express higher levels of IL-10 than TIE22 TAMs
F4/80+TIE22 TAMs and F4/80+TIE2+ TEMs were analyzed for
expression of intracellular IL-10 by flow cytometry in two dif-
ferent mammary tumor models: the spontaneous MMTV-PyMT
and syngeneic 4T1 models. CD11b+Gr1+ cells from the spleens
were also analyzed. In both tumor models, TEMs were the main
FIGURE 3. ANGPT2-treated TEMs induce expan-
sion of Tregs. Human CD14+ monocytes were cocul-
tured with CD3+ T cells in the presence of CD3/CD28
Dynabeads, 300 ng/ml ANGPT2, 100 U/ml IFN-g, 5
ng/ml IL-4, or medium alone (control). ANGPT2-
treated monocyte/T cell cocultures were also incubated
in the presence of nonspecific IgG or neutralizing IL-
10 Ab. After 5 d, the proportion of CD25+FOXP3+
cells was assessed by flow cytometry on CD3+CD4+-
gated cells. A, Representative dot plots with percen-
tages of gated cells shown. B, Graphic representation
of the percentage of CD25+FOXP3+ double-positive
cells from A (expressed as percentage of control). C,
T cells from ANGPT2-treated monocyte cocultures
were incubated with CFSE-labeled autologous CD3+
T cells for 5 d. CFSE median fluorescence intensity
(MFI) of CD3+-gated cells is shown graphically. Pooled
data from at least three independent experiments are
shown. *p , 0.05, **p , 0.01 as compared with con-
trol, ‡p, 0.05 as compared with IL-4, †††p , 0.001 as
compared with control + IgG, xxp , 0.01 as compared
with ANGPT2 + IgG.
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source of IL-10 among the total F4/80+ macrophage population,
and IL-10 expression by TEMs was comparable to CD11b+Gr1+
cells (Fig. 5A). These data suggest that in mammary tumors—
where ANGPT2 is upregulated (6–8)—TEMs are stimulated to
express high levels of IL-10 to suppress antitumor immunity and
to expand the Treg population.
ANGPT2 expression in tumors upregulates TEM-derived IL-10
and Treg infiltration
We measured ANGPT2 expression in the 4T1 tumor model by
Western blot over the course of several weeks after tumor cell
injection (day 0). Unexpectedly, we observed a dynamic, not
constitutive, pattern of ANGPT2 expression (Fig. 5B). Several
isoforms of ANGPT2 were detected including the unglycosylated
(55 kDa) and glycosylated forms (70 kDa) (19). Lysates from
tumor tissue displayed high levels of ANGPT2 during the early
days of tumor growth and then decreased as tumors became larger.
Interestingly, IL-10 expression from the same tumor lysates fol-
lowed a similar dynamic pattern to ANGPT2 expression. IL-10
was also upregulated during the early days of tumor growth (Fig.
5B).
We then quantified intracellular IL-10 in TEMs to determine
whether increased levels of ANGPT2 induce TEMs to upregulate
IL-10. Tumors from various days posttumor cell injection were
enzymatically digested and analyzed by flow cytometry. As ex-
pected, F4/80+TIE2+ TEMs displayed increased IL-10 expression
during the early time points when ANGPT2 levels were highest
(Fig. 5C). We then hypothesized that TEM-derived IL-10 may
influence Treg prevalence in tumors. Strikingly, the proportion
of tumor CD3+CD4+FOXP3+ Tregs was greatest on day 12 mim-
FIGURE 4. Treg frequency correlates
with ANGPT2 levels and TEM abundance
in tumors. A and B, Effect of ANGPT2
overexpression: Lewis lung carcinoma cells
were inoculated s.c. into TIE1-tTA–driven
ANGPT2 DT mice then excised after 2 wk
(5, 14). C and D, Effect of TEM depletion:
bone marrow from Tie2-thymidine kinase
(tk) transgenic mice was infused into sub-
lethally irradiated FVB mice. After 6 wk,
N202 mammary tumor cells were injected
s.c., and tumors were allowed to establish
for 2 wk before treatment with GCV to
deplete TEMs. PBS- and GCV-treated mice
were sacrificed after 3 wk (2). Frozen tumor
sections were stained with anti-CD3 (blue),
-CD4 (red), and -FOXP3 (green), and rep-
resentative images are shown. FOXP3-ex-
pressing CD3+CD4+ T cells are denoted by
white arrows. The number of cells per high-
powered field (HPF) and the proportion of
cells among whole populations are repre-
sented graphically. *p , 0.05, **p , 0.01.
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icking ANGPT2 expression patterns and upregulation of IL-10
by TEMs (Fig. 5C). On day 12, the frequency of FOXP3-ex-
pressing CD3+CD4+ cells increased ∼10-fold when compared
with other days. These data provide a direct link between
ANGPT2 expression, IL-10 production by TEMs, and Treg abun-
dance in tumors.
Tumor TEMs are immunosuppressive ex vivo
To determine whether TEMs in tumors modulate T cell behavior,
we isolated F4/80+TIE22 TAMs and F4/80+TIE2+ TEMs from
4T1 tumors as well as splenic CD11b+Gr1+ cells by FACS (Sup-
plemental Fig. 1). Myeloid subpopulations were then incubated
with CFSE-labeled CD3+ T cells ex vivo. TEMs and CD11b+Gr1+
cells exhibited a significantly greater ability to inhibit the pro-
liferation of T cells when compared with TIE2- TAMs (Fig. 6).
Blocking IL-10 activity with Abs reduced the suppressive effect of
TEMs and CD11b+Gr1+ cells, suggesting that IL-10 mediates the
ability of TEMs to prevent T cell proliferation.
Discussion
To our knowledge, this study shows for the first time that ANGPT2
stimulates human TEMs to markedly suppress T cell proliferation.
We previously reported that the immunosuppressive cytokine IL-
10 is upregulated by TEMs in response to ANGPT2 stimulation
FIGURE 5. ANGPT2 expression levels are associ-
ated with IL-10 production by TEMs and tumor-in-
filtrating Tregs. A, MMTV-PyMTand 4T1 tumors were
excised, enzymatically dispersed, stained with F4/80-
FITC, TIE2-PE, IL-10-allophycocyanin, CD11b-Alexa
700, or control Abs, and analyzed by flow cytometry.
Gates were placed around CD11b+ cells and macro-
phage subpopulations were identified as F4/80+TIE22
TAMs or F4/80+TIE2+ TEMs. CD11b+Gr1+ cells were
identified in spleens of tumor-bearing mice. Repre-
sentative histograms are shown of IL-10 expression.
Gray peaks represent fluorescence minus one allo-
phycocyanin isotype control. IL-10 expression is also
represented graphically. **p , 0.01, ***p , 0.001 as
compared with TAMs. B, Western blot analysis of
ANGPT2 and IL-10 expression in 4T1 whole tumor
lysates at various days posttumor cell injection (day 0).
b-Actin was used as a loading control. C, Histograms
of IL-10 expression by TEMs and dot plots of FOXP3
expression from CD3+CD4+-gated cells in 4T1 tumors
with percentage of positive cells displayed above the
gate.
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(5), and we demonstrate in this study that TEMs are the pre-
dominant source of IL-10 among all F4/80+ macrophages in two
different mammary tumor models. Moreover, ANGPT2-induced,
TEM-derived IL-10 suppressed T cell proliferation and expanded
CD4+CD25highFOXP3+ Tregs in vitro. These data indicate that
TEMs promote tumor progression not only by angiogenic stimu-
lation but also through subversion of antitumor immunity and
induction of tolerance via expansion of Tregs.
We chose to use mixed cultures of both TIE22 and TIE+ human
monocytes in our cocultures, because this represents the monocyte
heterogeneity present in peripheral blood and tumors. Because
TIE22 monocytes do not respond to ANGPT2 (4, 5), the effects
elicited by ANGPT2 in our cocultures represent the responses of
TEMs to this cytokine.
The main source of ANGPT2 in tumors is endothelial cells (6–8),
so newly recruited TEMs undergoing diapedesis likely encounter
high levels of ANGPT2 as they enter the tumor. ANGPT2 may
then skew TEM phenotype toward a more M2-like polarization
through upregulation of proangiogenic and immunosuppressive
genes (3, 5, 11). Our data indicate that ANGPT2 is critical for the
suppressive ability of TEMs as well as their expression of IL-10,
and this notion is supported by several observations presented in
this study. The varied expression levels of ANGPT2 as tumors
progressed and expanded surprised us. However, publications by
other groups using ANGPT2 knockout mice have shown that
ANGPT2 is essential during the early stages of tumorigenesis but
dispensable for later stages (20). Our data corroborate their find-
ings and suggest that ANGPT2 helps to establish the initial im-
munosuppressive environment via upregulation of IL-10 by TEMs
and Treg expansion.
In addition to IL-10, other macrophage-derived cytokines and
enzymes have been implicated in suppression of T cell proliferation
including TGF-b, cyclooxygenase-2–induced PGE2, inducible NO
synthase (iNOS)2, and arginase 1 (ARG1) (10, 12, 18, 21–23).
Pucci et al. (11) reported that tumor TEMs express higher levels of
Arg1 and lower levels of Tgfb, Cox-2, and Nos2 mRNA than
TIE22 TAMs, although differences at the protein level for these
molecules have yet to be confirmed. It is possible that ANGPT2
also stimulates the expression of one or more of these immuno-
suppressive factors by TEMs. Il-10 mRNA expression levels did
not differ between TEMs and TAMs (11), whereas we found
TEMs expressed significantly more IL-10 protein than TAMs.
This is not altogether surprising considering IL-10 is constitu-
tively transcribed in many cell types and highly dependent on
posttranscriptional regulation (24–27).
Myeloid-derived suppressor cells (MDSCs) also produce IL-10
and ARG1 (18, 21–23). However, TEMs and the classical CD11b+
Gr1+ MDSCs do not appear to be overlapping populations. TEMs
do not express Gr1—a commonly used marker to identify MDSCs
in secondary lymphoid organs and blood of tumor-bearing mice as
well as circulating inflammatory monocytes (18, 22). Rather,
TEMs share a related gene signature with circulating Gr12 resi-
dent monocytes (1, 2, 11), and splenic CD11b+Gr1+ MDSCs from
lymphoma-bearing mice fail to express TIE2 (22). It remains to be
seen whether TEMs in tumors and MDSCs in distant, secondary
lymphoid organs work in concert to suppress antitumor immune
responses. In addition, TEMs can now be classified as MDSCs,
because the heterogeneous myeloid cells within this group are
defined by their functional ability to inhibit T cell proliferation,
rather than their surface marker expression (28, 29).
FIGURE 6. Tumor TEMs inhibit T cell proliferation. F4/80+TIE22 TAMs and F4/80+TIE2+ TEMs from 4T1 tumors as well as CD11b+Gr1+ cells and
CD3+ from spleens were isolated by FACS. Myeloid cell subpopulations were cultured with CFSE-labeled CD3+ T cells for 3 d. A, Representative his-
tograms of T cell proliferation following incubation with percentages of the gated cells shown. B, Graphic representation of the percentage of gated cells
from A (expressed as percentage of TAM group). Combined data from four independent experiments are shown. **p, 0.01 as compared with TAMs, ‡p,
0.05, ‡‡p , 0.01 as compared with TAM + IgG, †p , 0.05 as compared with ANGPT2 + IgG, xp , 0.05 as compared with CD11b+Gr1+ cells + IgG.
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Although TEMs and classic MDSCs are likely different myeloid
cell populations, a recent publication characterizing CD11b+F4/
80+ TAMs as MHC-IIhigh and MHC-IIlow subsets indicate that
TEMs make up a fraction of the MHC-IIlow cell population (30).
In fact, the gene signature, phenotype, and superior proangiogenic
abilities of TEMs and MHC-IIlow TAMs are analogous (11, 30).
Interestingly, Ag processing by MHC-IIlow cells is less efficient
than MHC-IIhigh cells, but both subpopulations inhibit T cell
proliferation when compared with splenic dendritic cells. MHC-
IIhigh and MHC-IIlow cells are equally capable of suppressing anti–
CD3-stimulated T cells with each subset using different mecha-
nisms to accomplish this. MHC-IIhigh cell-mediated suppression is
iNOS dependent, whereas the molecule(s) used by MHC-IIlow
cells is unknown. These data, together with the data presented in
this paper, suggest that TEMs use IL-10, not ARG1 or iNOS, to
inhibit T cell proliferation. However, the equivalent immunosup-
pressive potential of MHC-IIhigh and MHC-IIlow cells contrasts
with our own data showing that TEMs possess significantly
greater ability to suppress T cell proliferation than TIE22 TAMs.
Varying levels of ANGPT2 in different tumor models may explain
this discrepancy, because ANGPT2 may drive TEMs’ T cell-
inhibitory functions. Moreover, the shaping of different T cell
populations (i.e., expansion of Tregs by TEMs) in the tumor mi-
croenvironment may be more important to tumor progression than
inhibiting T cell proliferation (30).
In summary, we demonstrate a novel tumor-promoting function
for TEMs: the ability to suppress T cell proliferation and expand
Tregs via ANGPT2-induced IL-10. These data suggest that in-
hibition of the ANGPT2–TIE2 interaction in tumors could impede
angiogenesis and reinitiate antitumor immunity (31).
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